drugset
drugset / Trial / NCT05616468

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

NCT05616468 ↗

Phase 0 Unknown 23 enrolled The Affiliated Hospital of Xuzhou Medical University Guangzhou Bioresette Biomedical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an exploratory study to evaluate the safety and preliminary effectiveness of BGT007 cells in the treatment of recurrent/metastatic nasopharyngeal carcinoma

Timeline

Start
2022-12-30
Primary completion
2024-12-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BGT007 Cell therapy 500000 cells/kg Intravenous
Subject BGT007 Cell therapy 1e+06 cells/kg Intravenous
Subject BGT007 Cell therapy 3e+06 cells/kg Intravenous
Subject BGT007 Cell therapy 6e+06 cells/kg Intravenous
Subject BGT007 Cell therapy 1e+07 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 250 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 350 mg/m2 Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

nasopharyngeal carcinoma